Tollys

Tollys is a biopharmaceutical startup with a focus on immuno-oncology, founded in 2015 in France. The company's mission is to develop specific TLR3 agonists that have demonstrated efficacy in preclinical models for inducing anti-tumor responses and preventing recurrences, particularly in Non-Muscle Invasive Bladder cancer (NMIBC) unresponsive to BCG treatment. Tollys aims to leverage the properties of TLR3 agonists, particularly TL-532, to activate and recruit patient tumor-specific cytotoxic T lymphocytes in the tumor bed, leading to anti-tumor effects and in-situ auto vaccination against recurrences.

Through its groundbreaking discoveries and patented TLR3 agonists, Tollys has the potential to address a high medical need indication with a potential for accelerated market approval. With its last €2.30M Series A investment from Investisseurs privés in May 26, 2020, Tollys is poised to enter clinical trials and potentially revolutionize the treatment of various cancers by harnessing the potential of TLR3 agonists. The company's innovative approach and promising lead candidate, TL-532, position Tollys as a significant player in the immuno-oncology space, with broad indication potential across multiple cancer types.